

진주종 유래 섬유아세포에서의 Insulin-Like Growth Factor I과 Binding Protein의 역할

을지의과대학교 이비인후과학교실

이창훈 · 조진생 · 박경유 · 김준우 · 이관원 · 이병권 · 이재수

The Role of Insulin-Like Growth Factor I and Binding Protein in Cholesteatoma Fibroblasts

Chang Hoon Lee, MD, Chin Saeng Cho, MD, Kyung-You Park, MD, Joon Woo Kim, MD,
Gwan Won Lee, MD, Byung Kwon Lee, MD and Jae Soo Lee, MD

Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Eulji University,
Daejeon, Korea

—ABSTRACT—

Background and Objectives : Insulin like growth factor-I is an important growth regulator for epidermis and its activity is regulated by specific insulin like growth factor binding protein. Authors observed the expression of mRNA of Insulin-like Growth FactorI (IGF-I) and mRNA of Insulin-like Growth Factor Binding Protein (IGFBP) in fibroblast of patient with cholesteatoma to find out the function of fibroblast in the progress of cholesteatoma. **Materials and Method** : During the operation in middle ears, the cholesteatoma and normal skin tissue were extracted from 10 patients with Cholesteatoma. Some cytokines were added such as Interferon β , Interferon γ and TNF α to those extracted fibroblast. We analyzed the expression of IGF-I, IGFBP-3, and IGFBP-5 by semi-quantative RT-PCR. **Results** : After stimulation by inflammatory cytokine, the expression of IGF-I from cholesteatoma was significantly increased, while the expression of IGFBP-5 was significantly reduced. **Conclusion** : These results indicate that cholesteatoma fibroblast could play an important role in the proliferation of cholesteatoma tissue. (J Clinical Otolaryngol 2003;14:113-117)

KEY WORDS : Cholesteatoma · Fibroblasts · Cytokines.

서 론

: 2003 4 6
: 2003 5 21
: , 301 - 070 24 1)

: (042) 259 - 1324 · : (042) 259 - 1321
E - mail : cscho@emc.eulji.ac.kr

Insulin-like growth factor (IGF) binding protein (IGFBP) 3, 4, 5

IGFBP-3, IGFBP-5

재료 및 방법

재 료

1, 10

방 법

200 IU/ml (Gibco BRL, U.S.A)
 200 ug/ml (Gibco BRL, U.S.A)
 100 mm 75% 60~90
 4 0.05% trypsin - 0.02% EDTA
 12, 15 ml 5% fetal calf serum (FCS, Gibco BRL, U.S.A)
 10 ml 1~2 가 5~10

3, 10% FCS가 DMEM (Dulbecco's modified Eagle's medium, Gibco BRL, U.S.A) 가

10% fetal calf serum (FCS), 10% fetal calf serum (FCS) IFN- γ (1000 U/ml; Genzyme, Cambridge, Mass.), IFN- β (500 U/ml; Maruho, Osaka, Japan), TNF- α (1000 U/ml; R & D Systems, Minneapolis, Minn) 가 RNA 8 . 5 passage

(Reverse transcription - polymerase chain reaction)

RNA acid-guanidinium Thiocyanate-phenol-chloroform method RNA prepmate (Bioneer K-3070) 8 RNA (1 μ g of each sample) DMEM with 10% FCS, TNF (1000 U/ml), INF (500 U/ml), INF (1000 U/ml) 가 25 10, 42 54, 99 5, 4 5 cDNA 2 mm MgCl₂, 50 mm KCl, 10 mM Tris-HCl, PH 8.3, 0.025 U/ μ l recombinant Taq DNA polymerase, 0.5 μ M of each of the forward & reverse primers 가 25 μ l가

oligonucleotide primers mRNA primer for human G3PDH 5' - CCCATCACCATCTTCCAG - 3' upstream & 5' - CCTGCTTCACCACCCTTCT - 3' downstream ; for IGF - I 5' - ACATTGCTCTCAACATCTCCC - 3' upstream & 5' - GCAATACATCTCCAGCCTCC - 3' downstream ; IGF - IBP3 5' - AA-




Fig. 1. RT-PCR products of IGF-I, IGFBP3, IGFBP5 derived from normal skin fibroblasts (A) and cholesteatoma fibroblasts (B) (Lane1 : control, Lane2 : TNF α , Lane3 : TNF β , Lane 4 : IFN γ).

ATGGAAGACACACTGAAT - 3' upstream & 5' - CTCTTTGCTGACTACTGGAA - 3' downstream ; for IGF - IBP5 5' - CCGGCAGGACGAGGAGAAGC - 3' upstream & 5' - GGGGGTGAGGGAAAGGTT - GG - 3' downstream .

G3PDH, IGF - I, IGFBP - 5 94 1
 , 60 1 , 72 1 20, 28, 26 cycles ,
 IGFBP - 3 94 1 , 52 1 ,
 72 1 16 cycles .

Products 5% acrylamide/Tris - borate EDTA gel
 2% agarose gel 100 bp - Mw
 marker (Fig. 1).

scan peak areas NIH image software

arbitrary units(means \pm SD)

Student t test




Fig. 2. IGF-I Expression of Cholesteatoma fibroblasts (*p<0.05).

가 (p<0.05)(Figs. 1 and 2).

결 과

IGF-I

(Fig. 1).

(TNF - , IFN - , IFN -)

)

IFN - , IFN -)

IGFBP3

(TNF -

, IFN - , IFN -)

IGFBP5

(TNF - , (TNF - , IFN - , IFN -)




Fig. 3. IGFBP-I Expression of Cholesteatoma fibroblasts (*p<0.05).

(TNF- α , IFN- γ , IFN- β) (p<0.05) (Fig. 1 and 3).

고찰

3)4) 가 5-7) IGFBP-5 (matrix) 8) basal, parabasal, upper layer cell nuclei cdk2 cdk4 9) 가 10) 가 11)

12) 가 13)14) network가 15) 가 IGF Binding protein down regulation binding protein IGFBP-3 IGFBP-5 IGF-I 가 , IGFBP- IGFBP-3 (matrix) 가

결론

IGF- 가 , IGF- BP-5 중심 단어 :

REFERENCES

- 1) Barreca A, De Luca M, Del Monte P, Bondanza S, Damonte G, Cariola G, et al. *In vitro paracrine regulation of human keratinocyte growth by fibroblast-derived insulin-like growth factors. J Cell Physiol* 1992;151:262-8.
- 2) Clemons DR, Busby W, Clarke JB, Parker A, Duan C, Nam TJ. *Modification of insulin-like growth factor binding proteins and their role in controlling IGF actions. Endocr J* 1998;45:S1-8.
- 3) Bujia J, Kim C, Ostos-aumente P, Lopez-Villarejo J, Kastenbauer E. *Enhanced epithelial proliferation due to elevated levels of interleukin-1 receptors in middle ear cholesteatomas. Eur Arch Otorhinolaryngol* 1997;254(1):6-8.
- 4) Ishibashi T, Shinogami M, Kaga K, Fukaya T. *Keratinocyte growth factor and receptor mRNA expression on cholesteatoma of the middle ear. Acta Otolaryngol* 1997;117(5):714-8.
- 5) Tanaka Y, Kojima H, Miyazaki H, Koga T, Moriyama H. *Roles of cytokines and cell-cycle regulating substances in proliferation of cholesteatoma epithelium. Laryngoscope* 1999;109(7):1102-7.
- 6) Chae SW, Song JJ, Suh HK, Jung HH, Lim HH, Hwang SJ. *Expression patterns of p27Kip1 and Ki-67 in cholesteatoma epithelium. Laryngoscope* 2000;110(11):1898-901.
- 7) Bujia J, Kim C, Holly A, Sudhoff H, Ostos P, Kastenbauer E. *Epidermal growth factor receptor (EGF-R) in human middle ear cholesteatoma: an analysis of protein production and gene expression. Am J Otol* 1996;17:203-6.
- 8) Chung JW, Yoon TH. *Different production of interleukin-1 alpha, interleukin-1 beta and interleukin-8 from cholesteatomatous and normal epithelium. Acta Otolaryngol* 1998;118(3):386-91.
- 9) Paukkoene K, Naukkarinen A, Horsmanheimo M. *The development of manifest psoriatic lesions is linked with the invasion of CD8⁺ T cells and CD11c⁺ macrophages into the epidermis. Arch Dermatol Res* 1992;284:375-89.
- 10) Sudhoff H, Borkowski G, Bujia J, Hildmann H, Fisseler-Eckhoff A. *Immunohistochemical studies with middle ear mucosal remnants in cholesteatoma. HNO* 1997;45(8):630-5.
- 11) Chao WY, Huang CC. *An immunohistochemical study of cyto-keratin expression in human middle ear cholesteatoma. Arch Otorhinolaryngol* 1989;246:37-42.
- 12) Marcio C, Rubin JS, Csaky KG. *Regulation of keratinocyte growth factor gene expression by interleukin 1. J Biol Chem* 1995;270:12607-13.
- 13) Saiag P, Coulomb B, Lebreton C, Bell E, Dubertret L. *Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. Science* 1985;230:669-72.
- 14) Krueger GG, Jorgensen CM. *Experimental models for psoriasis. J Invest Dermatol* 1990;95:56S-8S.
- 15) Weber L, Mauch C, Kirsch E, Muller P, Krieg T. *Modulation of collagen type synthesis in organ and cell cultures of fibroblast. J Invest Dermatol* 1986;87:217-20.